Debate seemed certain to bubble this week over the future of Human Genome Sciences Inc.'s deal with Novartis AG for the lackluster hepatitis C virus candidate Albuferon, in light of news due Monday from HGS and probably from another Novartis HCV partner, Idenix Pharmaceuticals Inc.